A drug that helps prevent colon cancer and other diseases has been developed at the Sloan Kettering Institute (SKI) Cancer Center at New York University (NYU) through the first phase human clinical trial (humans received the treatment). The research was conducted by the lab of Kristin Thomas-Yang PhD Head of the Human Compound Discovery Lab at SKI as part of the BRAIN Initiative letterhead. The Human Compound Discovery Lab known for its trial-stage work conducted this research not for profit but for charity in partnership with Rutgers Cancer Institute of New Jersey at Rutgers Robert Wood Johnson Medical School Dr. Mehdi Hasan Professor of Pharmacology at Rutgers-New Brunswick and one of the studys authors explained that Boston Childrens Hospital (BC-H) was chosen as the study site. BC-H is one of the largest and most sophisticated research sites in New York State and the largest institution in the New York City area.
This groundbreaking research involved the participation of NYU Associate Professor of Human Pharmacology and Physiology PhD Yuxiao Xu PhD and NYU Professor of Cell Developmental Biology Elizabeth A. Rubin PhD. Amazing results have helped Barnes-Collins University Beth Israel Deaconess Medical Center (BIDMC) and Jackson Laboratories for Cancer Research (KIHR) rev up the technology and speed of cancer treatment research in patients.
Read More